Re: Nader Al Nakouzi, Sylvestre le Moulec, Laurence Albigès, et al. Cabazitaxel Remains Active in Patients Progressing after Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. Eur Urol. in press. http://dx.doi.org/10.1016/j.eururo.2014.04.015